

National Pharmaceutical Pricing Authority

Subject: Minutes of the 65th meeting of the Multidisciplinary Committee of Experts held on 23.1.2025 at 3:00 PM.

65th meeting of the Multidisciplinary Committee of Experts was held on 23.1.2025 at 3:00PM under the convenorship of Shri Sanjay Kumar, Advisor (Cost). The following members attended the meeting: -

1. Shri Ranga Chandrashekar, Joint Drugs Controller, CDSCO through Video Conferencing
2. Dr. J. J. Cherian, Scientist-E (Med), ICMR through Video Conferencing
3. Dr. Rakesh Kr. Singh, Associate Professor, NIPER Raebareli, through Video Conferencing
4. Dr. Jai Prakash, Indian Pharmacopoeia Commission – Co-opted member
5. Prof. Y. K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member

The following officers of NPPA attended and presented the cases before the Committee:

1. Ms. Rashmi Tahiliani, Director (Pricing)
2. Shri Mahaveer Saini, Deputy Director (Pricing)
3. Ms. Yuvika Panwar, Assistant Director (Pricing)

Agenda Item No. 1: Retail price fixation under Para 5 of DPCO, 2013- Each 5 ml contains: Metformin Hydrochloride IP 500 mg for M/ s Eris therapeutics Limited (Manufacturer and Marketer) (F. No. 4255).

1.1 The Committee noted that the matter was earlier placed in 64th meeting of MDC held on 06.12.2024, wherein the Committee deliberated up on the matter and directed that MAT & PTR details may be sought from M/s Franco Indian Pharmaceuticals Pvt. Ltd.

1.2 The company vide email dated 23.12.2024 informed that they have neither manufactured nor marketed the aforesaid formulation since 2008. They have not undertaken any production or sale of this product under the provisions of DPCO 2013. Hence, they are unable to provide any information.

1.3 In view of the above, since, no data is available for price fixation of Metformin 500mg/5ml Oral liquid, the committee deliberated upon the matter in detail and recommended the retail price based on ceiling price fixed for other oral dosage form of Metformin 500mg i.e. Metformin 500mg tablet. The details are as follows:

- Applicant's formulation is each 5ml containing Metformin Hydrochloride IP 500mg
- Ceiling price of each tablet containing 500mg is Rs. 2.02 per tablet (S.O. No. 1547 (E) dated 26.03.2024)

- Therefore, worked out price for each 5ml of 500mg of applied formulation = Rs. 2.02. The per ml worked out price excluding GST is Rs. 0.40/ml (2.02/5)
- Claimed price is Rs. 18 per 5ML including GST i.e. Rs. 3.21 per ml excluding GST

1.4 The committee recommended the retail price of Rs. 0.40/ml of the subject formulation.

Agenda Item No. 2: Application for grant of separate price/special price for Omeprazole Delayed release orally disintegrating tablet 20 mg "OMEZ ODT" under the provision of Para 11 (3) or Para 32(3) DPCO 2013.

2.1 The Committee noted that the matter was earlier deliberated in the 64th meeting of MDC held on 06.12.2024, wherein the Committee recommended to reject the application for special/separate price for Omeprazole Delayed release orally disintegrating tablet 20 mg. In this connection, the applicant vide email dated 24.12.2024 filed representation against the recommendation of the MDC and requested to grant an opportunity for making a personal representation to NPPA or in person hearing in front of Multi-Disciplinary Committee.

2.2 As per the directions of the Competent Authority, the matter was again placed before the MDC and the applicant gave a detailed presentation of the case. The Committee noted that the applicant mentioned that approximately 8-19% of the general population in India is estimated to be suffering from GERD (Gastro Esophageal Reflux Disease). PPIs (Proton Pump Inhibitors) like Omeprazole have been used for its management for many decades with established clinical effectiveness & safety profile. However, 49% of GERD patients have alarming symptoms of which Dysphagia is the most common in almost two-third of GERD cases. The applicant also stated that the subject formulation does not have Sodium bicarbonate. Applicant stated that these facts have been taken from a survey conducted by clinicians to assess clinical profiling of patients with Acid Peptic Disorders in India.

2.3 The Committee noted that the subject formulation is useful for a subset of population having Dysphagia for which other liquid formulations are also available. Since this does not have sodium bicarbonate as mentioned by the applicant, this could be useful for only subset of cardiac patients. The applicant informed that the label claim of the subject formulation and other already available formulation i.e. OMEZ Insta (Powder for oral suspension with Sodium bicarbonate as buffer) will be same. Hence, the committee noted that the usefulness of the subject formulation is limited to a subset of population (i.e. patients with GERD having cardiac disorders along with Dysphagia).

2.4 The committee deliberated upon the matter and directed the applicant to submit the study/supporting documents showing the usefulness of the subject formulation and other additional document in support of their claim.

Pr

Agenda Item No. 3: Application to fix a separate Ceiling Price under Paragraph 11(3) of DPCO-2013, of a Scheduled formulation of Amoxicillin 200 mg + Clavulanic acid 28.5 mg Suspension in a Dual Chamber Pack with Novel Technology, being introduced in India for the first time. -Seeking additional Price for Dual Chamber Pack over and above Existing Ceiling Price.

3.1 The committee noted that the matter relates to application filed by M/s Sun Pharmaceuticals Industries Limited on 29.09.2023 for a separate ceiling price for scheduled formulation 'Amoxicillin 200 mg + Clavulanic acid 28.5 mg suspension' in a dual chamber pack with novel technology first time in India under para 11(3) of DPCO, 2013. The company has further stated that they are incurring additional direct packing material cost of Rs. 0.34 per ml for the dual chamber pack.

3.2 The Committee recalled its deliberations in 56th, 57th and 59th meeting of MDC held on 15.12.2023, 27.2.2024 and 8.05.2024 respectively, wherein the Committee did not find the case fit for separate ceiling price under Para 11(3). Hence, the Committee in its 59th meeting held on 8.05.2024 recommended to reject the application. The minutes of the MDC meeting were uploaded on website. However, no representation was received from the company. Accordingly, the recommendation of the MDC was placed in 124th meeting of the Authority held on 07.06.2024, wherein the Authority accepted the recommendation of the MDC and rejected the application. The minutes of Authority meeting were uploaded on website. However, no representation was received from the company this time also. Rejection Letter was sent to the company on 25.06.2024.

3.3 Now, the company vide letter dated 20.11.2024 has written to DoP to that they again reinforce that Novel Packaging Technology of Dual Chamber Pack is an incremental innovation and they wish to reapply for separate price under Para 11 (3). The applicant has further mentioned that MDC may consider their request in view of submissions made vide letter dated 20.11.2024 or may think of bringing some additional subject matter expert to review their case. The company also stated that the Para 11(3) insists for 'Therapeutic Rationale' and not the 'therapeutic advantage' as observed by the MDC in its 59th meeting.

3.4 Accordingly DoP vide letter dated 02.12.2024 requested NPPA to examine the matter and place it before the MDC for its reconsideration. Hence, the Committee deliberated upon the request of the applicant and directed that the company may submit the additional supporting documents, if any, in justification of their claim and appear before the committee in next meeting to present the case.

Agenda Item No. 4: Application under para 11 (3) of DPCO, 2013 for special retail price of Paracetamol and Phenylephrine Hydrochloride sachet (Each sachet containing Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg) by M/s GlaxoSmithKline Asia Private Limited.

4.1 The committee noted that M/s GlaxoSmithKline Asia Private Limited on 18.11.2024 applied for retail price under Para 11(3) of DPCO, 2013 for the formulation

"Paracetamol and Phenylephrine Hydrochloride sachet - Each sachet containing Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg". The applicant has submitted the following documents in respect of their claim:

- a. Scientific Rationale of the Formulation
- b. DCGI permission at Sl. No. 885 dated 24.12.2008
- c. SLA license no. MNB/05/232 dated 12.09.2024 & revised on 18.10.2024, valid till 04.12.2025
- d. Pack shot and the screenshot of other formulations sold in India
- e. CA certified Data of Quarterly production & sales in respect of the scheduled formulations marketed by the company
- f. Three Scientific journals to support the claim

4.2 The Committee noted that the applicant in the Scientific Rationale of the Formulation has mentioned the following:

- Paracetamol being sparingly soluble in water and associated with unacceptable taste and unpalatable bitterness, there is a need to develop innovative dosage form which can help in optimization of therapeutic benefits combined with organoleptic attributes for patient compliance.
- The solubility of Paracetamol is found to improve with increasing temperature of fluids. Study suggests that hot drink of paracetamol achieving faster and greater early drug absorption in comparison with a standard tablet formulation and scintigraphic data supports the promise that more rapid gastric emptying of the hot drink contributed to the earlier appearance of paracetamol in the plasma
- The proposed formulation is specifically designed for improved solubility in warm fluids along with acceptable organoleptic properties. This will result in Paracetamol reaching the bloodstream and being bioavailable faster than tablet formulations, thereby resulting in a quicker alleviation of discomfort and associated symptoms
- The new product will be supplied as powder packed in individual sachets, which would need to be reconstituted in hot water and consumed as a hot drink for the treatment of fever associated with cold, nasal congestion in adults

4.3 The Committee noted the applicant has given photographs of subject formulations of other companies available in the market, however the pack shots are not clear. After detailed deliberations, the committee directed that the applicant may be asked to appear before the committee in next meeting to present their case along with supporting documents including samples of the formulations referred in the application.

Agenda Item No.5: Retail price fixation under Para 5 of DPCO, 2013 for each hard gelatin capsule contains Cefixime IP eq. to Cefixime anhydrous 200mg + Erdosteine 300mg for M/s Macleods Pharmaceuticals Limited (Manufacturer & Marketer) under DPCO, 2013 (File No.4347).

5.1 The Committee deliberated upon the matter and recommended the retail price each hard gelatin capsule contains Cefixime IP eq. to Cefixime anhydrous 200mg + Erdosteine 300mg for M/s Macleods Pharmaceuticals Limited (Manufacturer & Marketer) at Rs. 39.08 per tablet as below:

S. No.	Particulars	Month	Amount (Rs.) Excluding GST
	Each hard gelatin capsule contains Cefixime IP eq. to Cefixime anhydrous 200mg + Erdosteine 300mg		
(a)	Ceiling price of Cefixime 200mg capsule (S.O. 1547(E) dt. 23.03.2024)	May 2024	14.68
(b)	Derived retail price of Erdosteine 300mg	May 2024	27.34
(c)	Total		42.02
(d)	Less 20% of the lower of (a) & (b) based on inference drawn from the Pronab Sen Committee Report		2.94
(e)	Worked out retail price (a)+(b)+(c)-(d)		39.08
(f)	Claimed retail price		43.00
(g)	Recommended retail price (lower of worked out & claimed)		39.08

Agenda Item No. 6: Each film coated bilayer tablet contains: Dapagliflozin Propanediol USP eq to Dapagliflozin 10mg + Metoprolol Succinate eq to Metoprolol Tartrate 25mg (as extended release) for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Zydus Healthcare Limited (Marketer) F No (4361).

6.1 The Committee deliberated upon the matter and recommended the retail price for Each film coated bilayer tablet contains: Dapagliflozin Propanediol USP eq to Dapagliflozin 10mg + Metoprolol Succinate eq to Metoprolol Tartrate 25mg (as extended release) for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Zydus Healthcare Limited (Marketer) at Rs. 15.96 per tablet as below:

1	Manufacturer Name	M/s Exemed Pharmaceuticals
2	Marketer Name	M/s Zydus Healthcare Ltd. (Applicant)
3	Date of Application	09.12.2024
4	Patented Component	Dapagliflozin
5	Patent Holder	M/s Astra Zeneca
6	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
7	Date of Patent Expiry	02.10.2020

Calculation of Retail price

S. No.	Particulars	Month	Amount (Rs.) Excluding GST
A	Dapagliflozin Price as on 6 months prior to application date excluding price of Patent/ license holder	May, 2024	12.60
B	Metoprolol Succinate eq to Metoprolol Tartrate 25mg (as extended release) (Ceiling Price [SO. 1547(E) dated 26.03.2024].	May, 2024	4.20
C	Total (A+B)		16.80
D	Less: 20% of the lower of (A) and (B) based on inference drawn from the Pronab Sen Committee Report		0.84
E	Worked out retail price (C-D)		15.96

S. No.	Particulars	Month	Amount (Rs.) Excluding GST
F	Claimed retail price		70.00
G	Recommended retail price (lower of worked out & claimed)		15.96

Agenda Item No. 7: Application by M/s Pulse Pharmaceuticals Private limited for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (iii) for the formulation "Paracetamol Oral solution (taste masked) 125mg/5ml and 250mg/5ml produced utilizing indigenously developed innovative LYOMATRIX Technology offering Novel Drug Delivery System"

7.1 The Committee noted that the matter was earlier deliberated in 62nd and 63rd meeting of MDC held on 25.9.2024 and 22.10.2024 respectively. The company had given a detailed presentation of its case in the 63rd meeting. After detailed deliberation, the Committee observed that the delivery system as developed by the company does not fall under the definition of 'New Drug Delivery System' as solutions are covered under oral liquid dosage forms which are already in existence. Further, other formulations are also available that are taste masked. Accordingly, the committee recommended that the proposal does not qualify under the provisions of Para 32 (iii) of the DPCO for exemption from price control.

7.2 The minutes of the 63rd meeting of MDC were uploaded on NPPA's website on 28.10.2024. The applicant vide email dated 05.11.2024 referred the recommendation of the MDC and requested to present their case again to thoroughly address the points and any other relevant concerns raised by the MDC.

7.3 The recommendation of the Committee along with the representation of the company dated 24.12.2024 was placed before the Authority in its 128th meeting held on 12.12.2024, wherein the Authority directed that the applicant may be given one more opportunity to represent the case before the Committee.

7.4 Accordingly, the applicant was asked to appear before the Committee to present their case again. However, the applicant vide email dated 22.1.2025 informed "*we are currently working diligently and scientifically to derive more robust conclusions, which will require some additional time. Once these are ready, we will reach out for new date to share our updated findings.*"

7.5 Accordingly, the Committee directed that the company may be directed to submit the additional data/ documents as requested by them at the earliest.

The meeting ended with a vote of thanks to all.

Rashmi
4/2/25
(Rashmi Tahiliani)
Director (Pricing)

Copy to:
All members of the Committee.

Computation of Retail Price based on May 2024 Data under Para 5 of DPCO, 2013

Erdosteine 300mg	Number of Companies consisting of Market Share of 1% & Above					1
	Sum of MAT value considered for price calculation (in Lakhs)					26.10
	Sum of PTR per unit considered for price calculation					23.57
	Number of Packs considered					1
	Average PTR					23.57
	Add : 16% Retailer Margin					3.77
	Retail Price (without local taxes)					27.34
	% Reduction with compared to Highest Price					0.00%

Minimum Price (Rs.)			23.57
Maximum Price (Rs.)			23.57
Average of all considered (Rs.)			23.57
Retail Price (Rs.)			27.34

[illegible]

Computation of Retail Price based on May, 2024 Data under Para 5 of DPCO, 2013

Computation of Retail Price based on May, 2024 Data under Para 3 of DCCO, 2013									
Dapagliflozin 10mg tablet	Number of Companies cosisting of Market Share of 1% & Above								18
	Sum of MAT value considered for price calculation (in Lakhs)								34,706.53
	Sum of PTR per unit considered for price calculation								260.69
	Number of Packs considered								24
	Average PTR								10.86
	Add : 16% Retailer Margin								1.74
	Retail Price (without local taxes)								12.60
	% Reduction with compared to Highest Price								26.07%

Minimum Price (Rs.)			4.21
Maximum Price (Rs.)			14.69
Average of all considered (Rs.)			10.86
Retail Price (Rs.)			12.6

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	TOTAL MAT	3,97,65,04,489	100%	M3		
								MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	4 DAPA 10 MG TABLET 10	4 DAPA	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	85	1760435.00	0.04%	0.04%	N	8.50	
2	4 DAPA M 10 MG TABLET 10	4 DAPA M	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	110	706320.00	0.02%	0.02%	N	11.00	
3	GLEDEPA 10 MG TABLET 14	GLEDEPA	ABBOTT HEALTHCARE PVT. LTD	10 MG	14	TABLET	573.5						
4	LVEFFECT 10 MG TABLET 15	LVEFFECT	ABBOTT HEALTHCARE PVT. LTD	10 MG	15	TABLET	176.79						
5	GLUJECT 10 MG TABLET 15	GLUJECT	ABBOTT HEALTHCARE PVT. LTD	10 MG	15	TABLET	176.79						
6	DAXIGA 10 MG TABLET 10	DAXIGA	ACMEDIX PHARMA LLP	10 MG	10	TABLET	31.43	8022947.52	0.20%	0.20%	N	3.14	
7	DAPALEX 10 MG TABLET 10	DAPALEX	AJANTA PHARMA LTD	10 MG	10	TABLET	117.86	1613621.26	0.04%	0.72%	N	11.79	
8	DAPANTA 10 MG TABLET 10	DAPANTA	AJANTA PHARMA LTD	10 MG	10	TABLET	38.4	542416.64	0.01%	0.01%	N	3.84	
9	DAPALEX 10 MG TABLET 15	DAPALEX	AJANTA PHARMA LTD	10 MG	15	TABLET	174.29	26951798.09	0.68%	0.72%	N	11.62	
10	DAPASIS 10 MG TABLET 10	DAPASIS	AKESS PHARMA (P) LTD	10 MG	10	TABLET	109.07	13699106.73	0.34%	0.34%	N	10.91	
11	SWITDAPA 10 MG TABLET 10	SWITDAPA	AKUMENTIS HEALTHCARE LTD	10 MG	10	TABLET	85	10969335.00	0.28%	0.28%	N	8.50	
12	LINADAPA 10 MG TABLET 10	LINADAPA	AKUMENTIS HEALTHCARE LTD	10 MG	10	TABLET	125	10765750.00	0.27%	0.27%	N	12.50	
13	VOAGE 10 MG TABLET 10	VOAGE	ALEMBIC LTD	10 MG	10	TABLET	92.86	82723314.42	2.08%	2.08%	Y	9.29	9.29
14	DAPANORM 10 MG TABLET 10	DAPANORM	ALKEM LABORATORIES LTD.	10 MG	10	TABLET	125	432569250.00	10.88%	10.88%	Y	12.50	12.50
15	FLOZIMAX 10 MG TABLET 15	FLOZIMAX	ALNICHE LIFE SCIENCES PVT.LTD	10 MG	15	TABLET	139.29	36211.34	0.00%	0.00%	N	9.29	
16	DAPAZOL 10 MG TABLET 10	DAPAZOL	ALTEUS BIOGENICS PVT.LTD.	10 MG	10	TABLET	116.68	13134378.73	0.33%	0.33%	N	11.67	
17	DAPCARD 10 MG TABLET 10	DAPCARD	ALVIO PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	92.86	9318222.42	0.23%	0.23%	N	9.29	
18	DAPAYES 10 MG TABLET 10	DAPAYES	ANAX LIFE SCIENCES PVT.LTD	10 MG	10	TABLET	78.57	281581.86	0.01%	0.01%	N	7.86	
19	DAPATREND 10 MG TABLET 14	DAPATREND	ANTHEM BIOPHARMA PVT LTD	10 MG	14	TABLET	117.86	2173543.22	0.05%	0.05%	N	8.42	
20	DAPRICA 10 MG TABLET 10	DAPRICA	APRICA HEALTHCARE PVT LTD	10 MG	10	TABLET	120.8	33829630.96	0.85%	0.85%	N	12.08	
21	GLUFLOZIN 10 MG TABLET 15	GLUFLOZIN	ARISTO PHARMACEUTICALS PVT.LTD	10 MG	15	TABLET	121.43	37779392.40	0.95%	0.95%	N	8.10	
22	FORXIGA 10 MG TABLET 14	FORXIGA	ASTRAZENCA PHARMA INDIA LTD	10 MG	14	TABLET	362.86						
23	DAPATEN 10 MG TABLET 15	DAPATEN	BAL PHARMA	10 MG	15	TABLET	128.93	707526.25	0.02%	0.02%	N	8.60	
24	BIOXIGA 10 MG TABLET 10	BIOXIGA	BIOS LAB PVT.LTD	10 MG	10	TABLET	102.85	721910.95	0.02%	0.02%	N	10.29	
25	DIABIZ (BLUE) 10 MG TABLET 15	DIABIZ (BLUE)	BLUE CROSS LABORATORIES LTD	10 MG	15	TABLET	75	15902850.00	0.40%	0.40%	N	5.00	
26	DAPADEL 10 MG TABLET 10	DAPADEL	CADELL HEALTH CARE PVT.LTD	10 MG	10	TABLET	92.14	2443314.40	0.06%	0.06%	N	9.21	
27	ZANELLA 10 MG TABLET 10	ZANELLA	CADOMED PHARMACEUTICALS INDIA PVT.LTD	10 MG	10	TABLET	86.98	672044.54	0.02%	0.02%	N	8.70	
28	DAPASACH 10 MG TABLET 10	DAPASACH	CIPLA LTD.	10 MG	10	TABLET	71.43	17009054.46	0.43%	0.43%	N	7.14	
29	GLIFDAPA 10 MG TABLET 10	GLIFDAPA	CMR LIFE SCIENCES	10 MG	10	TABLET	96.43	2060516.24	0.05%	0.05%	N	9.64	
30	DAPABITE 10 MG TABLET 10	DAPABITE	CORONA	10 MG	10	TABLET	128.75	85791017.50	2.16%	2.16%	Y	12.88	12.88
31	DIOSGLT 10 MG TABLET 15	DIOSGLT	DIOS LIFESCIENCES PRIVATE LIMITED	10 MG	15	TABLET	147.32	561756.28	0.01%	0.01%	N	9.82	
32	DAPLO 10 MG TABLET 10	DAPLO	DR. REDDYS LABORATORIES LTD	10 MG	10	TABLET	142.5	120343869.94	3.03%	3.03%	Y	14.25	14.25
33	ESGEDAP 10 MG TABLET 14	ESGEDAP	EAST WEST PHARMA	10 MG	14	TABLET	159.51	7702888.17	0.19%	0.19%	N	11.39	
34	DAPACOOOL 10 MG TABLET 10	DAPACOOOL	ECON HEALTHCARE PVT LTD	10 MG	10	TABLET	78.57	392535.72	0.01%	0.01%	N	7.86	
35	DAPADER 10 MG TABLET 14	DAPADER	ELDER PROJECTS LIMITED	10 MG	14	TABLET	55.14	4595880.04	0.12%	0.12%	N	3.94	

36	ELDAPA 10 MG TABLET 10	ELDAPA	EL-DORADO BIO-TECH PVT LTD	10 MG	10	TABLET	78.57	2511296.94	0.06%	0.06%	N	7.86	
37	XGLET 10 MG TABLET 10	XGLET	ELINOR PHARMA	10 MG	10	TABLET	140	3096520.00	0.08%	0.08%	N	14.00	
38	EMILDAP 10 MG TABLET 15	EMILDAP	EMCURE PHARMACEUTICALS LTD	10 MG	15	TABLET	175.46	11205301.14	0.28%	0.28%	N	11.70	
39	DAPAGZA 10 MG TABLET 15	DAPAGZA	EMCURE PHARMACEUTICALS LTD	10 MG	15	TABLET	175.46	4540272.44	0.11%	0.11%	N	11.70	
40	DAPAZEP 10 MG TABLET 10	DAPAZEP	ERGOS LIFE SCIENCES	10 MG	10	TABLET	85.71	491375.43	0.01%	0.01%	N	8.57	
41	GLUXIT 10 MG TABLET 10	GLUXIT	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	108.75	189017781.54	4.75%	4.75%	Y	10.88	10.88
42	MYODA 10 MG TABLET 10	MYODA	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	125.21	6100238.86	0.15%	0.15%	N	12.52	
43	DIFLUP 10 MG TABLET 10	DIFLUP	EXELTIS	10 MG	10	TABLET	121.24	573685.77	0.01%	0.01%	N	12.12	
44	DIABFLOZ 10 MG TABLET 10	DIABFLOZ	FINECURE PHARMACEUTICALS	10 MG	10	TABLET	82.14	45089.15	0.00%	0.00%	N	8.21	
45	FLOZIDAP 10 MG TABLET 10	FLOZIDAP	FRANCO INDIAN PHARMACEUTICALS PVT LTD	10 MG	10	TABLET	103.57	9828378.72	0.25%	0.25%	N	10.36	
46	DEXIGLU 10 MG TABLET 10	DEXIGLU	FUSION HEALTHCARE PVT LTD	10 MG	10	TABLET	114.29	16220964.43	0.41%	0.41%	N	11.43	
47	DAPA GOLD 10 MG TABLET 15	DAPA GOLD	HBC LIFESCIENCES PVT LTD	10 MG	15	TABLET	175.5	21255824.98	0.53%	0.53%	N	11.70	
48	DAPADOT 10 MG TABLET 10	DAPADOT	HETERO HEALTHCARE LTD	10 MG	10	TABLET	103.57	583616.95	0.01%	0.01%	N	10.36	
49	DAPARAY 10 MG TABLET 10	DAPARAY	ICON LIFESCIENCES	10 MG	10	TABLET	82.14	3577892.21	0.09%	0.09%	N	8.21	
50	DIMPRIDE 10 MG TABLET 10	DIMPRIDE	INDCHEMIE HEALTH SPECIALITIES PVT. LTD.	10 MG	10	TABLET	99.29	1133097.48	0.03%	0.03%	N	9.93	
51	DIGLIZ 10 MG TABLET 10	DIGLIZ	INDCHEMIE HEALTH SPECIALITIES PVT. LTD.	10 MG	10	TABLET	99.29	350394.41	0.01%	0.01%	N	9.93	
52	DEPAJA 10 MG TABLET 10	DEPAJA	INDOCO REMEDIES LTD	10 MG	10	TABLET	82.14	22259.94	0.00%	0.00%	N	8.21	
53	DAPARYL 10 MG TABLET 10	DAPARYL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	111.43	248978313.41	6.26%	6.26%	Y	11.14	11.14
54	DAPAVEL 10 MG TABLET 10	DAPAVEL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	111.43	414032262.93	10.41%	10.41%	Y	11.14	11.14
55	T2C 10 MG TABLET 15	T2C	IPCA LABORATORIES PVT LTD.	10 MG	15	TABLET	200.29	28588994.02	0.72%	0.72%	N	13.35	
56	DAPABLESS 10 MG TABLET 10	DAPABLESS	JAGSONPAL PHARMACEUTICALS LTD	10 MG	10	TABLET	50	7650.00	0.00%	0.00%	N	5.00	
57	JODAPA 10 MG TABLET 15	JODAPA	JARUN PHARMACEUTICALS	10 MG	15	TABLET	117.86	12017916.36	0.30%	0.30%	N	7.86	
58	DAPACOSE 10 MG TABLET 10	DAPACOSE	JB CHEMICALS	10 MG	10	TABLET	103.62	79344010.02	2.00%	2.00%	Y	10.36	10.36
59	DAPAEASE 10 MG TABLET 10	DAPAEASE	JUBILANT GENERICS LIMITED	10 MG	10	TABLET	113.93	5981099.65	0.15%	0.15%	N	11.39	
60	DAPAEASE V 10 MG TABLET SR 15	DAPAEASE V	JUBILANT GENERICS LIMITED	10 MG	15	TABLET SR	148.5	5983969.50	0.15%	0.15%	N	9.90	
61	DEGLIFLO 10 MG TABLET 10	DEGLIFLO	KANAD LABS	10 MG	10	TABLET	203.39	1623458.98	0.04%	0.04%	N	20.34	
62	DMBEST 10 MG TABLET 10	DMBEST	KEPLER HEALTH CARE	10 MG	10	TABLET	92.86	2278320.10	0.06%	0.06%	N	9.29	
63	DAGLIPACK 10 MG TABLET 10	DAGLIPACK	KOYE PHARMACEUTICALS PVT. LTD.	10 MG	10	TABLET	99.29	1355705.66	0.03%	0.03%	N	9.93	
64	DAPACONIC 10 MG TABLET 15	DAPACONIC	LA RENON HEALTHCARE PVT.LTD	10 MG	15	TABLET	198.57	7631640.81	0.19%	0.19%	N	13.24	
65	DAPAHENZ 10 MG TABLET 15	DAPAHENZ	LA RENON HEALTHCARE PVT.LTD	10 MG	15	TABLET	198.57	49753302.06	1.25%	1.25%	Y	13.24	13.24
66	DAPAFORD 10 MG TABLET 15	DAPAFORD	LEEFORD HEALTHCARE	10 MG	15	TABLET	42	1151571.00	0.03%	0.03%	N	2.80	
67	DIFOZIN 10 MG TABLET 14	DIFOZIN	LINCOLN PHARMACEUTICALS LTD	10 MG	14	TABLET	149.29	526097.96	0.01%	0.01%	N	10.66	
68	SUGAFLO 10 MG TABLET 15	SUGAFLO	LLOYD HEALTHCARE PVT.LTD	10 MG	15	TABLET	176.8	17704575.20	0.45%	0.45%	N	11.79	
69	DAPATURN 10 MG TABLET 10	DAPATURN	LUPIN LTD	10 MG	10	TABLET	113.86	62512460.55	1.57%	1.57%	Y	11.39	11.39
70	DAMITA 10 MG TABLET 10	DAMITA	MACLEODS PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	117.07	80224675.97	2.02%	2.02%	Y	11.71	11.71
71	DAPAMAC 10 MG TABLET 10	DAPAMAC	MACLEODS PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	117.07	185987821.23	4.68%	4.68%	Y	11.71	11.71
72	JUSTOZA 10 MG TABLET 10	JUSTOZA	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	70.71	2945212.92	0.07%	1.40%	Y	7.07	7.07
73	SGLTD 10 MG TABLET 10	SGLTD	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	77.79	80841568.47	2.03%	2.03%	Y	7.78	7.78
74	JUSTOZA 10 MG TABLET 15	JUSTOZA	MANKIND PHARMACEUTICALS LTD.	10 MG	15	TABLET	116.68	52748928.09	1.33%	1.40%	Y	7.78	7.78
75	DAPABLIS 10 MG TABLET 10	DAPABLIS	MED MANOR ORGANICS PVT LTD.	10 MG	10	TABLET	98.57	2418168.68	0.06%	0.06%	N	9.86	
76	GLIFLODAP 10 MG TABLET 10	GLIFLODAP	MEDICURE LIFE SCIENCES PVT.LTD	10 MG	10	TABLET	68.57	2639876.43	0.07%	0.07%	N	6.86	
77	DAPANOVA 10 MG TABLET 15	DAPANOVA	MEDLEY PHARMACEUTICALS	10 MG	15	TABLET	168.57	46906257.87	1.18%	1.18%	Y	11.24	11.24
78	ZUCAPRIDE 10 MG TABLET 15	ZUCAPRIDE	MICRO LABS LTD	10 MG	15	TABLET	151.43	85474131.00	2.15%	2.15%	Y	10.10	10.10
79	DAJIO 10 MG TABLET 15	DAJIO	MICRO LABS LTD	10 MG	15	TABLET	150.71	57564229.71	1.45%	1.45%	Y	10.05	10.05
80	VIVADAPA 10 MG TABLET 10	VIVADAPA	MITOCH PHARMA PVT LTD	10 MG	10	TABLET	100	18299800.00	0.46%	0.46%	N	10.00	
81	DAPAONE 10 MG TABLET 10	DAPAONE	MSN LABORATORIES LTD	10 MG	10	TABLET	117.64	48412267.04	1.22%	1.22%	Y	11.76	11.76
82	DAPNAT 10 MG TABLET 30	DAPNAT	NATCO PHARMA LTD	10 MG	30	TABLET	70.71	74316.21	0.00%	0.00%	N	2.36	
83	DAPNAT 10 MG TABLET 10	DAPNAT	NATCO PHARMA LTD	10 MG	10	TABLET	70.71	9648790.68	0.24%	0.24%	N	7.07	
84	DAPANEU 10 MG TABLET 15	DAPANEU	NEUCURE LIFESCIENCES PVT.LTD	10 MG	15	TABLET	181.5	8338506.00	0.21%	0.21%	N	12.10	
85	DAPACARE 10 MG TABLET 10	DAPACARE	OCTALIFE PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	64.29	601827.96	0.02%	0.02%	N	6.43	
86	OPSICA 10 MG TABLET 15	OPSICA	OPSISCARE LIFESCIENCSE PVT LTD	10 MG	15	TABLET	150	3621000.00	0.09%	0.09%	N	10.00	
87	OZODAP 10 MG TABLET 15	OZODAP	OZONE PHARMACEUTICALS	10 MG	15	TABLET	53.57	3055739.94	0.08%	0.08%	N	3.57	
88	DAPABEST 10 MG TABLET 10	DAPABEST	PANACEA BIOTEC LTD	10 MG	10	TABLET	100	7284.80	0.00%	0.00%	N	10.00	
89	DAPAKEY 10 MG TABLET 10	DAPAKEY	PRECIA PHARMA	10 MG	10	TABLET	103.57	1222954.56	0.03%	0.03%	N	10.36	
90	GLIFOPRIME 10 MG TABLET 10	GLIFOPRIME	PRIMUS REMEDIES PVT LTD	10 MG	10	TABLET	62.5	2480327.50	0.06%	0.06%	N	6.25	
91	DPO 10 MG TABLET 10	DPO	RPG LIFE SCIENCES LTD.	10 MG	10	TABLET	94.29	4161360.87	0.10%	0.10%	N	9.43	
92	DAPASAN 10 MG TABLET 14	DAPASAN	SANATRA HEALTH CARE PVT.LTD	10 MG	14	TABLET	150	1970550.00	0.05%	0.05%	N	10.71	
93	SHIDAPA 10 MG TABLET 10	SHIDAPA	SHINE PHARMACEUTICALS LTD	10 MG	10	TABLET	94.29	404015.34	0.01%	0.01%	N	9.43	
94	DAPASIG 10 MG TABLET 10	DAPASIG	SIGNOVA PHARMA (P) LTD	10 MG	10	TABLET	84.29	631247.81	0.02%	0.02%	N	8.43	
95	DAPAGREAT 10 MG TABLET 15	DAPAGREAT	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	150	750.00	0.00%	0.00%	N	10.00	

96	MDAPA 10 10 MG TABLET 15	MDAPA 10	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	96.43	96.43	0.00%	0.00%	N	6.43	
97	DAPASPEC 10 MG TABLET 10	DAPASPEC	SPECTRA THERAPEUTICS PVT. LTD.	10 MG	10	TABLET	96.43	9173096.61	0.23%	0.23%	N	9.64	
98	OXRA 10 MG TABLET 14	OXRA	SUN PHARMA LABORATORIES LTD.	10 MG	14	TABLET	155						
99	DAPEFY 10 MG TABLET 14	DAPEFY	SUN PHARMA LABORATORIES LTD.	10 MG	14	TABLET	141.43						
100	DAPAGAIN 10 MG TABLET 15	DAPAGAIN	SYSTOPIC LABORATORIES LTD-MEM	10 MG	15	TABLET	63.22	63674109.26	1.60%	1.60%	Y	4.21	4.21
101	DAPOXEE 10 MG TABLET 10	DAPOXEE	TALENT INDIA	10 MG	10	TABLET	77.86	454464.57	0.01%	0.01%	N	7.79	
102	DAPIXA 10 MG TABLET 10	DAPIXA	TAS MED (INDIA) PRIVATE LTD.	10 MG	10	TABLET	110	911130.00	0.02%	0.02%	N	11.00	
103	GLUCRETA 10 MG TABLET 10	GLUCRETA	TORRENT PHARMACEUTICALS LTD.	10 MG	10	TABLET	107.36	187742637.12	4.72%	4.72%	Y	10.74	10.74
104	DGSON 10 MG TABLET 10	DGSON	UNISON PHARMACEUTICALS	10 MG	10	TABLET	32.14	19023794.56	0.48%	0.48%	N	3.21	
105	UDAPA 10 MG TABLET 10	UDAPA	USV PVT LTD	10 MG	10	TABLET	100.86	570890704.68	14.36%	14.36%	Y	10.09	10.09
106	DAPGLIN 10 MG TABLET 10	DAPGLIN	VASU ORGANICS PVT.LTD	10 MG	10	TABLET	83.57	83.57	0.00%	0.00%	N	8.36	
107	DAPAVAS 10 MG TABLET 10	DAPAVAS	VASU ORGANICS PVT.LTD	10 MG	10	TABLET	91.93	728545.25	0.02%	0.02%	N	9.19	
108	FLOZIPA 10 MG TABLET 10	FLOZIPA	WALLACE PHARMACEUTICALS LTD.	10 MG	10	TABLET	100	7020300.00	0.18%	0.18%	N	10.00	
109	ZINODAP 10 MG TABLET 10	ZINODAP	WOCKHARDT LTD	10 MG	10	TABLET	187.39	13166728.49	0.33%	0.33%	N	18.74	
110	DAPASET 10 MG TABLET 14	DAPASET	WONSET HEALTH CARE PRIVATE LIMITED	10 MG	14	TABLET	103.57	2161054.89	0.05%	0.05%	N	7.40	
111	DAPAXIGA 10 MG TABLET 14	DAPAXIGA	ZERICO LIFESCIENCES PVT.LTD	10 MG	14	TABLET	139.29	71545.10	0.00%	0.00%	N	9.95	
112	DUPHABLESS 10 MG TABLET 10	DUPHABLESS	ZERICO LIFESCIENCES PVT.LTD	10 MG	10	TABLET	471.43	269657.96	0.01%	0.01%	N	47.14	
113	DAPAFOR 10 MG TABLET 10	DAPAFOR	ZUVENTUS HEALTHCARE LTD	10 MG	10	TABLET	82.43	2552710.62	0.06%	0.06%	N	8.24	
114	DAPAGLYN 10 MG TABLET 15	DAPAGLYN	ZYDUS CADILA - ZHL	10 MG	15	TABLET	220.39	141228115.90	3.55%	6.09%	Y	14.69	14.69
115	DAPAGLYN 10 MG TABLET 10	DAPAGLYN	ZYDUS CADILA - ZHL	10 MG	10	TABLET	146.93	100946346.41	2.54%	6.09%	Y	14.69	14.69
		Rs. Per tablet											
	Worked out Retail Price	12.60	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Dapagliflozin i.e. M/s Astra Zeneca & License holder i.e. M/s Sun Pharma and M/s Abbott Healthcare is not considered for price fixation.